Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.57M
Average 0.49M
BCYC Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Bicycle Therapeutics plcNASDAQ: BCYC
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$544.14M, compared with -$783.85M a year earlier.
Context
- Net debt amounted to 83.4% of total assets at the end of Q1 FY2026, down 5.3 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +30.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (610.59M) USD
- Year-over-year change
- +29.8%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (610.59M) | +29.8% |
| FY2024 | 2024-12-31 | (870.03M) | -80.7% |
| FY2023 | 2023-12-31 | (481.47M) | -63.3% |
| FY2022 | 2022-12-31 | (294.83M) | +25.2% |
| FY2021 | 2021-12-31 | (394.34M) | — |
Net Debt vs competitors
How BCYC compares with its peers on the latest reported figures
- BCYC's Mar 2026 net debt of -$544.14M is the lowest of the 10 companies compared; the peer median is -$51.95M.
- Its year-over-year change of +30.6% is the 2nd highest of 9, against a peer median of -27.6%.
- Net debt amounts to 83.4% of total assets for BCYC, versus a peer median of 23.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $308.73M | -24.8% | -11.5% | 107.9% | |
| Mar 2026 | $19.62M | -54.8% | +46.1% | 7.3% | |
| Mar 2026 | -$44.39M | -30.3% | — | 12.8% | |
| Mar 2026 | -$45.38M | -30.9% | — | 22.1% | |
| Mar 2026 | -$51.95M | +52.6% | — | 10.1% | |
| Dec 2025 | -$77.77M | — | — | 23.2% | |
| Mar 2026 | -$114.34M | -144.8% | — | 39.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | -$146.66M | -16.5% | — | 95.3% |
| Mar 2026 | -$321.81M | +21.1% | — | 92.0% | |
| Mar 2026 | -$544.14M | +30.6% | — | 83.4% | |
| Peer median (excluding BCYC) | -$51.95M | -27.6% | +17.3% | 23.2% | |
Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 438.68M | 339.15M | 526.42M | 879.52M | 628.11M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 11.91M | 21.21M | 24.04M | 35.65M | 35.59M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 7.97M | 9.02M | 11.41M | 13.43M | (35.59M) |
| Total Current Assets | 458.56M | 369.38M | 561.87M | 928.61M | 628.11M |
| Property, Plant & Equipment (Net) | 17.79M | 32.77M | 27.68M | 17.19M | 21.91M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 547K | 547K | 58K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.45M | 8.46M | 5.24M | 10.53M | 12.75M |
| Total Non-current Assets | 21.24M | 41.23M | 33.48M | 28.26M | 34.71M |
| Total Assets | 479.79M | 410.61M | 595.34M | 956.87M | 717.6M |
| Account Payables | 2.72M | 6.47M | 13.05M | 15.79M | 9.67M |
| Short-term Debt | 0 | 0 | 4.88M | 0 | 2.76M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 19.27M | 20.42M | 24.98M | 10.19M | 2.96M |
| Other Current Liabilities | 7M | 13.4M | 13.24M | 16.57M | 17.14M |
| Total Current Liabilities | 36.24M | 53.34M | 69.54M | 67.23M | 56.98M |
| Long-term Debt | 29.87M | 30.32M | 30.7M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 52.07M | 41.46M | 110.22M | 91.47M | 35.51M |
| Other Non-current Liabilities | 3.28M | 3.83M | 4.58M | 1.12M | 363K |
| Total Non-current Liabilities | 97.3M | 86.48M | 154.88M | 96.58M | 50.64M |
| Total Liabilities | 133.54M | 139.83M | 224.41M | 163.81M | 107.62M |
| Common Stock | 384K | 387K | 550K | 890K | 894K |
| Retained Earnings | (218.38M) | (331.1M) | (511.76M) | (680.79M) | (899.75M) |
| Accumulated OCI | (3.39M) | 387K | (1.3M) | 119K | (3.51M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 346.25M | 270.78M | 370.93M | 793.06M | 609.98M |
| Total Debt | 44.34M | 44.33M | 44.96M | 9.49M | 17.52M |
| Net Debt | (394.34M) | (294.83M) | (481.47M) | (870.03M) | (610.59M) |
Bicycle Therapeutics plc
NASDAQ:BCYC
Intrinsic Alpha fair value
Locked
Current Price
$3.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.